GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (STU:NNFN) » Definitions » Institutional Ownership

MannKind (STU:NNFN) Institutional Ownership : 27.84% (As of Apr. 29, 2025)


View and export this data going back to . Start your Free Trial

What is MannKind Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MannKind's institutional ownership is 27.84%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MannKind's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MannKind's Float Percentage Of Total Shares Outstanding is 98.53%.


MannKind Institutional Ownership Historical Data

The historical data trend for MannKind's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Institutional Ownership Chart

MannKind Historical Data

The historical data trend for MannKind can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 27.55 28.46 28.91 30.84 31.22 31.50 28.07 27.75 27.75 27.84

MannKind Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


MannKind Business Description

Traded in Other Exchanges
Address
1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

MannKind Headlines

No Headlines